

## CURRICULUM VITAE

Young Joo Min MD, PhD

### Current Position

Professor

Division of Hematology-Oncology

Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea

### Education

1984-1990 Hanyang University College of Medicine, Korea (MD)

1996-1998 Ulsan University Graduate School, Korea (MS)

2001-2003 Inje University Graduate School, Korea (PhD)

GCP Training\_2015.12.22

### Honors

2004 The Best Scientific Research Award, Korean Association of Internal Medicine

### Qualifications

1990 Korean Medical License (No 42005)

1998 Korean Board Certification of Internal Medicine (No 5506)

2000 Korean Board Certification of Hematology/Oncology (No 600177)

2015.12.22 GCP Certification of Attendance

2012.10.19 Clinical trial training & education essential course for investigators

### Professional Experience

1990-1991 Rotating Intern, Hanyang University Hospital, Korea

1991-1994 Medical Military Service in Army

1994-1998 Resident in Medicine, Asan Medical Center, Korea

1998-2000 Fellow in Hematology/Oncology, Asan Medical Center, Korea

2000-2003 Instructor in Medicine, Ulsan University Hospital, Korea  
2003-2007 Assistant Professor, Ulsan University Hospital, Korea  
2006-2007 Guest Researcher, NIH/NCI, MD, USA  
2007-2012 Associate Professor, Ulsan University Hospital, Korea  
2012-present Professor, Ulsan University Hospital, Korea

#### Societies/Professional Affiliations

American Society of Clinical Oncology: Active Member  
American Association for Cancer Research: Active Member  
Korean Society of Oncology: Member  
Korean Society of Hematology: Member  
Korean Society of Hematopoietic Stem Cell Transplantation: Member  
Korean Society of Internal Medicine: Member  
Korean Association for Clinical Oncology: Academic Member

#### Publications

1. Attitudes toward participating in Phase I clinical trials: an investigation with patient-family-physician triads. Shin DW, Cho J, Kim SY, Yang HK, Cho B, Shin DB, Chun MS, Min YJ, Kim YW, Park JH. *Jpn J Clin Oncol*. 2016 Dec;46(12):1095-110
1. Radotinib induces high cytotoxicity in c-KIT positive acute myeloid leukemia cells. Heo SK, Noh EK, Kim JY, Jo JC, Choi Y, Koh S, Baek JH, Min YJ, Kim H. *Eur J Pharmacol*. 2017 Jun 5;804:52-5
2. Cross-cultural application of the Korean version of the EORTC QLQ-ELD14 questionnaire for elderly patients with cancer. Goo AJ, Shin DW, Yang HK, Park JH, Kim SY, Shin JY, Kim YA, Kim C, Hong NS, Min YJ, Park K. *J Geriatr Oncol*. 2017 Jul;8(4):271-276
3. Realities of KRAS-mutated non-small cell lung cancer. Min YJ. *Korean J Intern Med*. 2017 May;32(3):442
4. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, Min YJ, Cho EK, Lee SS, Kim BS, Choi MY, Shim HS, Chung JH, La Choi Y, Lee MJ, Kim M, Kim JH, Ali SM, Ahn MJ, Cho BC. *J Clin Oncol*. 2017 Aug 10;35(23):2613-261
5. Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid

- leukemia cell death. Heo SK, Noh EK, Kim JY, Jeong YK, Jo JC, Choi Y, Koh S, Baek JH, Min YJ, Kim H. *Sci Rep*. 2017 Nov 10;7(1):15278. doi: 10.1038/s41598-017-15492-5
6. Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). Sun JM, Lee KH, Kim BS, Kim HG, Min YJ, Yi SY, Yun HJ, Jung SH, Lee SH, Ahn JS, Park K, Ahn MJ. *Br J Cancer*. 2018 Mar 6;118(5):648-653.
  7. Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01). Ku BM, Heo MH, Kim JH, Cho BC, Cho EK, Min YJ, Lee KH, Sun JM, Lee SH, Ahn JS, Park K, Kim TJ, Lee HY, Kim H, Lee KJ, Ahn MJ. *J Pathol Transl Med*. 2018 May;52(3):148-156.
  8. Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulas V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC. *JAMA Oncol*. 2018 Sep 1;4(9):1189-1197
  9. Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. Lee JS, Lee KH, Cho EK, Kim DW, Kim SW, Kim JH, Cho BC, Kang JH, Han JY, Min YJ, Park K. *Lung Cancer*. 2018 Aug;122:234-242
  10. Rhein augments ATRA-induced differentiation of acute promyelocytic leukemia cells. Heo SK, Noh EK, Kim JY, Jegal S, Jeong Y, Cheon J, Koh S, Baek JH, Min YJ, Choi Y, Jo JC. *Phytomedicine*. 2018 Oct 1;49:66-74
  11. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csösz T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. *N Engl J Med*. 2018 Nov 22;379(21):2040-205